EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference » EQRx
Management will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference. The fireside chat is scheduled for Thursday, December 2nd at 4:45 p.m. ET. A webcast of the discussion can be accessed on the Investors portion of the Company’s website at https://investors.eqrx.com/.
EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
EQRx to leverage Evotec’s unique data-driven integrated drug discovery and development accelerator platform; partnership aims to build up jointly owned pipeline to deliver innovative, affordable and accessible medicines to patients
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
The series is moderated by Jami Rubin, EQRx’s chief financial officer, and features EQRx senior leadership team members, board directors, investors and external advisors.
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
Agreement with one of the largest public healthcare systems globally demonstrates EQRx’s commitment to offering new medicines to patients at radically lower prices